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Background: The aim of this study was to investigate the effect of two genetic polymorphisms 
in the coding regions (exon 3 and exon 4) of the EPHX1 gene, ie, 337T.C and 416A.G, 
respectively, on the metabolism of carbamazepine (CBZ) 10,11-epoxide (the active metabolite of 
CBZ) by evaluating the variation in serum CBZ 10,11-epoxide levels 4 hours after administration 
of the drug. Moreover, we reported the genotype frequencies of the CYP3A4*22 (rs 35599367, 
C.T) variant and its influence on the metabolism of CBZ.
Methods: The analysis was performed in 50 patients receiving CBZ as monotherapy. DNA 
was extracted from leukocytes using a commercially available kit. Serum CBZ 10,11-epoxide 
levels were measured by high-performance liquid chromatography. Allelic discrimination 
was performed using polymerase chain reaction-restriction fragment length polymorphism. 
Statistical analysis of the difference in mean values for CBZ 10,11-epoxide levels according 
to genotype was performed using the Student’s t-test with Statistical Package for the Social 
Sciences version 13 software.
Results: Fourteen percent of the study group were CC, 42% were CT, and 44% were TT for the 
EPHX1 337T.C variant. No GG homozygote was identified for the EPHX1 416A.G variant; 
64% were AA and 36% were AG. When we compared serum CBZ 10,11-epoxide levels 4 hours 
after drug administration, we found no statistically significant difference between the 337 CC, 
CT, and TT genotypes. Similarly, no difference in serum CBZ 10,11-epoxide levels was found 
between 416A.G AA and AG. Genotype frequencies for the CYP3A4*22 (rs 35599367 C.T) 
allelic variant were 94% for CC and 6% for CT, with no statistically significant difference in 
serum CBZ 10,11-epoxide levels between these genotypes 4 hours after administration of the 
drug (2.6±1.3 µg/µL and 2.5±1.2 µg/µL, respectively).
Conclusion: Although there is some evidence of involvement of these polymorphisms in 
enzyme activity in vitro, we found no interference with CBZ metabolism in vivo.
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Introduction
Epilepsy is the most common chronic neurological disorder and is characterized by 
recurrent unprovoked epileptic seizures. It has a prevalence of 5–10 per 1,000 and an 
incidence of 50–120 per 100,000 per year.1 Administration of antiepileptic drugs fails 
to control epileptic seizures in 70% of patients. Carbamazepine (CBZ) is one of the 
most commonly used anticonvulsants in the treatment of epilepsy. Two basic mecha-
nisms of action have been proposed, ie, enhancement of sodium channel inactivation by 
reducing high-frequency repetitive firing of action potentials and an effect on synaptic 
transmission.² CBZ is extensively metabolized in the liver, with less than 5% of an oral 
dose excreted unmodified in the urine. The enzymes involved in the primary  metabolism 
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of CBZ belong to the superfamily of cytochrome P450 (CYP) 
responsible for formation of reactive epoxides. Isoenzyme 
CYP3A4, the major form of CYP in the adult liver and 
responsible for the metabolism of most drugs (45%–60%), is 
involved in the formation of CBZ 10,11-epoxide, the active 
metabolite of CBZ. The latter is converted to the inactive 
water-soluble metabolite (CBZ 10,11-diol) by microsomal 
epoxide hydrolase, which is encoded by the EPHX1 gene. 
CBZ 10,11-diol is excreted in the urine.³
The aim of the present study was to investigate the 
effect of two genetic polymorphisms in the coding regions 
(exon 3 and exon 4) of the EPHX1 gene on the metabolism 
of CBZ 10,11-epoxide.4 These polymorphisms were carefully 
selected from previous reports in the literature and databases 
such as the dbSNP.5,6 We also evaluated the variation in serum 
CBZ 10,11-epoxide levels 4 hours after administration of the 
drug. Finally, we analyzed the genotypic frequencies of the 
CYP3A4*22 (rs 35599367, C.T) variant and its influence 
on serum levels of the CBZ metabolite.
Materials and methods
The patient characteristics are described in Table 1. Thirty-two 
of the 50 patients included in this study were male, the mean 
age of the group was 41±14 years, and all were from South 
Italy. All of the patients had partial or generalized tonic-clonic 
epileptic seizures. Blood samples for measurement of serum 
CBZ and metabolite levels, and molecular analysis were 
obtained from patients who were on maintenance mono-
therapy with CBZ. The dosage was established on the basis 
of clinical features and frequency of seizures. All patients 
had reached steady-state, and the average CBZ dose was 
13.5±7.4 mg/kg/day. None of the patients were being treated 
with other drugs (antiepileptic or nonantiepileptic) that could 
interfere with the metabolism of CBZ, and none reported 
significant ingestion of food known to interact with CBZ. The 
study was approved by the Ethics Committee of the Depart-
ment of Biopathology and Medial and Forensic Biotechnolo-
gies and all patients gave their written informed consent.
Serum CBZ and CBZ metabolite measurement, which 
is performed routinely for therapeutic drug monitoring in 
patients with epilepsy, was performed by high-performance 
liquid chromatography. Separation was obtained by isocratic 
elution with ultraviolet detection at 220 nm. The mobile phase 
was 63% phosphate buffer, 32% acetonitrile, 3.5% methyl 
alcohol, and 1.5% tetrahydrofuran. The limit of detection was 
0.5 µg/mL for CBZ, the intra-assay co efficient of variation was 
,3%, and the interassay coefficient of variation was ,5%.
Genomic DNA was extracted from leukocytes using a com-
mercial kit (Roche Diagnostics Corporation, Indianapolis, 
IN, USA). Allelic discrimination for EPHX1 337T.C, 
EPHX1 416A.G, and the CYP3A4*22 (rs 35599367 C.T) 
variant was carried out by polymerase chain reaction-re-
striction fragment length polymorphism (PCR-RFLP).7,8 For 
PCR amplification, we used the following primers: forward 
5’-GATCGATAAGTTCCGTTTCACC-3’ and reverse 5’-CT-
TAGTCTTGAAGTGAGGAT-3’ for identification of EPHX1 
337T.C; forward 5’-ACATCCACTTCATCCACGT-3’ 
and reverse 5’-ATGCCTCTGAGAAGCCAT-3’ for 
identif ication of EPHX1  416A.G; and forward 
5’-CTGAAGAGGAATCGGCTCTG-3’ and reverse 
5’-TTTTTACCATCCTTCCTCTATGC-3’ for identification 
of the allelic variant CYP3A4*22 (rs 35599367 C.T). The 
PCR mixture was performed in a total volume of 50 µL, 
containing 150 ng DNA, 0.2 mM of each deoxynucleotide 
triphosphate; 25 nmol of each primer, 5 µL of 10 × reaction 
buffer, and 1.5 mM MgCl
2
, with two units of Taq polymerase 
for EPHX1 337T.C and EPHX1 416A.G, and 1.5 units for 
CYP3A4*22. The PCR conditions were 94°C for 3 minutes, 
35 cycles of 94°C for 30 seconds, 55°C for 25 seconds, 
72°C for 20 seconds, and a final extension of 72°C for 
5 minutes. This protocol was used for both allelic variants 
of the EPHX1 gene. CYP3A4*22 was analyzed using the 
following protocol: 94°C for 3 minutes, 35 cycles of 94°C 
for one minute, 55°C for one minute, 72°C for one minute, 
and a final extension of 72°C for 5 minutes. The amplified 
PCR products were digested with 10 U EcoRV for EPHX1 
337T.C, 5 U RSAI for EPHX1 416A.G, and 6 U Dra III for 
CYP3A4*22 (rs 35599367, C.T) and overnight incubation 
at 37°C. The RFLP analysis was performed on 3% agarose 
gel and confirmed by direct sequencing. Statistical analysis 
of the difference in mean CBZ 10,11-epoxide levels between 
the genotypes was done with the Student’s t-test using Sta-
tistical Package for the Social Sciences version 13 software 
(SPSS Inc., Chicago, IL, USA). Differences in adjusted basal 
CBZ 10,11-epoxide levels between the genotypes were tested 
for using the Kruskal–Wallis test.
Table 1 characteristics of patients on cBZ monotherapy, with 
serum cBZ/cBZ 10,11-epoxide ratio indicated in the basal state 
and 4 hours after administration of the drug
Patients (n) 50
age, years 41±14
sex, male/female 32/18
Daily cBZ dose (mg/kg) 13.5±7.4
Basal cBZ/cBZ 10,11-epoxide ratio (µg/ml) 4.07±1.32
cBZ/cBZ 10,11-epoxide ratio after 4 hours (µg/ml) 4.39±1.68
Abbreviation: cBZ, carbamazepine.
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Results
Fourteen percent of the study group were CC, 42% were CT, 
and 44% were TT for the EPHX1 337T.C variant, and the 
frequency of the C allele was 0.35 (Table 2B); none were 
homozygous for the EPHX1 416A.G variant, with 64% 
and 36% being AA and AG, respectively (Table 2A). The 
frequency of the G allele was 0.18. We compared the distri-
bution of genotype frequencies with that of a representative 
control population used in previous studies in our laboratory 
and found no differences (data not shown). Patient charac-
teristics were not different between the EPHX1 and CYP3A4 
genotypes when we performed an analysis for daily CBZ 
dose, serum CBZ and CBZ 10,11-epoxide levels in the basal 
state and 4 hours after ingestion of the drug.
When we compared the mean values for CBZ 10,11-
epoxide at 4 hours between 337 CC (1.9±0.84 µg/µL), 
337 CT (2.9±1.3 µg/µL), and 337 TT (2.5±1.4 µg/µL), we 
found no statistically significant differences (P.0.05). The 
difference was also not statistically significant between AA 
(2.7±1.4 µg/µL) and AG (2.4±1.2 µg/µL) for the EPHX1 
416A.G variant. Moreover, we compared basal serum CBZ 
10,11-epoxide levels adjusted for the daily dose between 
EPHX1 337C.T and 416A.G genotypes to evaluate 
whether these variants can modulate serum levels of the active 
form of the drug, but no statistically significant differences 
were found (P=0.23 for EPHX1 377T.C and P=0.71 for 
EPHX1 416A.G). The combined effect of the two EPHX1 
polymorphisms on serum concentrations of CBZ, CBZ 
10,11-epoxide, and the corresponding value adjusted for daily 
dose was evaluated, but the analysis revealed no statistically 
significant differences (P=0.63).
The genotype frequencies were 94% CC and 6% CT for 
the CYP3A4*22 (rs 35599367, C.T) variant (Table 2C). 
The T allele frequency was 0.03. As for the EPHX1 variants, 
we found no differences in genotype distribution between 
the study group and the control group (data not shown). No 
statistically significant differences were found comparing 
serum CBZ 10,11-epoxide levels between the genotype CC 
(2.6±1.3 µg/µL) and genotype CT (2.5±1.2 µg/µL) groups 
4 hours after administration of the drug.
Discussion
Epilepsy is a common neurological disease characterized 
by recurrent seizures. The therapeutic goal is to maximize 
seizure control while minimizing adverse drug effects, thus 
preserving the patient’s quality of life. However, despite the 
introduction of a number of new antiepileptic drugs during 
recent years, about one third of the epilepsy population 
continues to show drug-resistance.9,10 It has been shown that 
the variability in individual response to antiepileptic drugs 
depends not only on environmental factors such as diet 
and smoking, but also on age, sex, weight, liver and renal 
function, disease heterogeneity, and genetic background.11 
Genetic background can predict drug efficacy and toxicity, 
so the effect of genetic polymorphisms on the metabolism 
of drugs is significant.
In the present study, we investigated the two best known 
polymorphisms of the EPHX1 gene coding for microsomal 
epoxide hydrolase, ie, 337T.C within exon 3 (resulting in 
substitution of Tyr with His at amino acid position 113) and 
416A.G within exon 4 (which codes for substitution of His 
with Arg at amino acid position 139).
Our results demonstrate that EPHX1 and CYP3A4 
polymorphisms do not affect serum CBZ 10,11-epoxide 
levels. To our knowledge, involvement of these variants in 
the metabolism of CBZ has not been well investigated, and 
there are conflicting reports in the literature. Makmor-Bakry 
et al demonstrated that EPHX1 337C.T and 416A.G poly-
morphisms were associated with the maintenance dose of 
CBZ, but no serum drug or metabolite levels were reported.12 
Moreover, the 377C.T polymorphism has been associated 
with a higher diol/epoxide ratio and the 416A.G polymor-
phism with a lower ratio, suggesting altered activity for the 
corresponding variant enzyme.13
It was reported that the frequency of the C allele for 
EPHX1 337T.C was 0.29 in a population from northern 
Italy, while the frequency of the G allele for EPHX1 416A.G 
was 0.16 in the same population.6 These values are compa-
rable with our data. Indeed, the frequency of the C allele for 
EPHX1 337T.C was 0.35 while the frequency of the G allele 
for EPHX1 416A.G was 0.18.
Table 2 genotype frequencies for EPHX1 416a.g (A), EPHX1 
337T.c (B), and CYP3A4*22 rs 35599367 (C) in epileptic patients 
on carbamazepine therapy
Genotype Frequencies
(a) EPHX1 416a.g (exon 4)
 aa 64% (32/50)
 ag 36% (18/50)
 gg /
(B) EPHX1 337T.c (exon 3)
 cc 14% (7/50)
 cT 42% (21/50)
 TT 44% (22/50)
(c) CYP3A4*22 rs 35599367 c.T
 cc 94% (47/50)
 cT 6% (3/50)
 TT /
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In vitro expression studies of the EPHX1 gene have 
shown that the 337T.C variant confers a 40% decrease in 
hydrolase activity and that the 416A.G variant confers a 
25% increase in activity. In our study, subjects with 337 TT 
did not show higher levels of circulating CBZ 10,11-epoxide 
4 hours after administration of the drug. Similarly, no sig-
nificant decrease was observed in subjects heterozygous for 
the 416 AG variant. The influence of microsomal epoxide 
hydrolase variants on the metabolism of CBZ is still under 
investigation.
In our study population, the frequency of the CYP3A4*22 
(rs 35599367, C.T) allele was 0.03, as reported in the lit-
erature for the Caucasian population.14 Although recently 
associated with low hepatic CYP3A4 expression and activity, 
this allelic variant did not appear to affect CBZ metabolism 
in the epileptic patients in our study. One of the limitations 
of this study was its relatively small sample size, so our 
results require validation in a larger cohort. However, it is 
challenging to obtain patients on monotherapy with CBZ, 
given that this drug is commonly used in combination with 
other antiepileptic drugs.
Conclusion
Although the literature contains some evidence of involve-
ment of these polymorphisms in CBZ metabolism in vitro, 
our results show no interference in vivo. However, our pre-
liminary findings require confirmation in a larger population 
of epileptic patients receiving CBZ. We intend to extend this 
study to include epileptic patients on polytherapy in order 
to assess the influence of different drugs on the activity of 
microsomal epoxide hydrolase, which is involved in the 
metabolism of CBZ.
Disclosure
The authors report no conflicts of interest in this work.
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